Paliperidone palmitate

Synonyms: 9-Hydroxyrisperidone palmitate
Paliperidone palmitate 是一种口服有效且可通过血脑屏障的多巴胺 D2 受体和 5-羟色胺 2A (5-HT2A) 受体竞争性拮抗剂,它通过与这两种受体结合竞争性地抑制多巴胺和 5-羟色胺的作用,调节神经递质系统的平衡,从而发挥抗精神病活性,主要用于精神分裂症的研究。
产品编号: MS-A45166 纯度: 99.93% CAS No.: 199739-10-1 分子式: C39H57FN4O4 分子量: 664.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Paliperidone palmitate 是一种口服有效且可通过血脑屏障的多巴胺 D2 受体和 5-羟色胺 2A (5-HT2A) 受体竞争性拮抗剂,它通过与这两种受体结合竞争性地抑制多巴胺和 5-羟色胺的作用,调节神经递质系统的平衡,从而发挥抗精神病活性,主要用于精神分裂症的研究。

生物实验数据

生物活性 Paliperidone palmitate is an orally active, blood-brain barrier-penetrant competitive antagonist of dopamine D2 receptors and serotonin 2A (5-HT2A) receptors that exerts antipsychotic activity by binding to dopamine D2 receptors and 5-HT2A receptors to competitively inhibit the actions of dopamine and serotonin and thereby modulate the balance of neurotransmitter systems, and is primarily used for the study of schizophrenia.
IC50 & Target

D2 Receptor

 

5-HT2A Receptor

 

体内研究
(In Vivo)

Paliperidone palmitate (小鼠 62.4 mg/kg、大鼠 20 mg/kg;肌肉注射;单剂量) 在 BALB/c 小鼠和 Sprague Dawley 大鼠模型中,与透明质酸酶 (HY-172442) 联合给药会在注射后的前 4 天改变 Paliperidone palmitate 的 depot 释放,增加血浆暴露量,但不影响 Paliperidone palmitate 的长效释放特性。在小鼠中,透明质酸酶会改变注射部位的组织形态,使巨噬细胞在肌细胞间浸润,在大鼠中,注射部位会形成有中央腔和坏死的肉芽肿。

Animal Model: BALB/c mice (female, about 20 g, 6-8 weeks old)+Sprague Dawley rats (male, about 250 g, 6-8 weeks old)
Dosage: Mice: 62.4 mg/kg of Paliperidone palmitate, 5 U or 15 U of hyaluronidase (dissolved in normal saline)
Rats: 20 mg/kg of Paliperidone palmitate, 5 U or 15 U of Hyaluronidase (dissolved in phosphate buffered saline)
Administration: Intramuscular injection, single dose; for mice, 4-week study period; for rats, 21-28-day study period
Result: In mice, co-administration of hyaluronidase increased paliperidone plasma exposures in the first week after injection. The overall long-acting release nature of the formulation was maintained. Macrophages showed infiltration between individual myocytes when paliperidone palmitate was co-administered with hyaluronidase.
In rats, co-administration of hyaluronidase also increased exposure in the first 4 days, but the effect was less than that in mice. The long-acting exposure was still maintained for about 20 days. Co-administration of hyaluronidase did not discernably affect the granulomas or the surrounding myocytes in rats. The lymph node retention of paliperidone palmitate was diminished upon treatment with hyaluronidase in both mice and rats. The biphasic plasma concentration-time profiles of paliperidone in both species could be described by an open first-order disposition model with parallel fast and slow absorption processes.
The macrophage infiltration and angiogenesis at the injection site affected the drug release and absorption, and the effect of hyaluronidase on these processes was different between mice and rats.
性状 固体
颜色 White to off-white

化学信息

分子量 664.89
分子式 C39H57FN4O4
CAS No. 199739-10-1
别名 9-Hydroxyrisperidone palmitate

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

Ethanol 中的溶解度 : 2 mg/mL (3.01 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol1 mM1.5040 mL7.5200 mL15.0401 mL37.6002 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础